Aspirin may block Niacin's uncomfortable flush, tiny study hints
NCT ID NCT01275300
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested whether taking a low dose of aspirin (81 mg) before niacin (600 mg) could reduce the flushing reaction that niacin often causes. Nine healthy adults with high cholesterol participated, providing urine and blood samples to measure prostaglandin levels. The study was small and exploratory, aiming to understand the body's response rather than prove a treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aspirin 81 mg and Niacin 600 mg
What this could lead to
If successful, this could help understand how to reduce the uncomfortable flushing side effect of niacin, potentially making it easier for people with high cholesterol to tolerate the medication.
What could go wrong
This is a very small pilot study with only 9 participants, so results may not apply to the general population. It is designed to measure biological markers, not to prove any treatment benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, 19104, United States